Active surveillance for clinically localized prostate cancer--a systematic review (Q38194533)

30 August 2017

1 reference

title

Active surveillance for clinically localized prostate cancer--a systematic review (English)

1 reference

30 August 2017

1 reference

1 reference

3

Laurence H Klotz

1 reference

30 August 2017

Frederik B Thomsen

1

1 reference

30 August 2017

Klaus Brasso

2

1 reference

30 August 2017

M Andreas Røder

4

1 reference

30 August 2017

Kasper D Berg

5

1 reference

30 August 2017

Peter Iversen

6

1 reference

30 August 2017

7 March 2014

1 reference

Journal of Surgical Oncology

30 August 2017

1 reference

30 August 2017

109

1 reference

30 August 2017

8

1 reference

30 August 2017

830-835

1 reference

Radical prostatectomy versus observation for localized prostate cancer

30 August 2017

1 reference

Pathologic findings in radical prostatectomy specimens from patients eligible for active surveillance with highly selective criteria: a multicenter study

21 January 2018

1 reference

Natural History of Early, Localized Prostate Cancer

21 January 2018

1 reference

20-year outcomes following conservative management of clinically localized prostate cancer

21 January 2018

1 reference

Guideline for the management of clinically localized prostate cancer: 2007 update.

21 January 2018

1 reference

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease

21 January 2018

1 reference

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

Active surveillance for the management of prostate cancer in a contemporary cohort

21 January 2018

1 reference

Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era.

21 January 2018

1 reference

Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer

21 January 2018

1 reference

Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment

21 January 2018

1 reference

Active surveillance program for prostate cancer: an update of the Johns Hopkins experience

21 January 2018

1 reference

Active surveillance for prostate cancer: an Australian experience.

21 January 2018

1 reference

Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer

21 January 2018

1 reference

Medium-term outcomes of active surveillance for localised prostate cancer.

21 January 2018

1 reference

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

21 January 2018

1 reference

Prostate cancer in Denmark 1978-2009--trends in incidence and mortality

21 January 2018

1 reference

Predicting 15-year prostate cancer specific mortality after radical prostatectomy

21 January 2018

1 reference

Timing of curative treatment for prostate cancer: a systematic review

21 January 2018

1 reference

Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?

21 January 2018

1 reference

Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database

21 January 2018

1 reference

Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial

21 January 2018

1 reference

The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma

21 January 2018

1 reference

Prostate cancer and the Will Rogers phenomenon.

21 January 2018

1 reference

Outcomes of active surveillance for men with intermediate-risk prostate cancer

21 January 2018

1 reference

Prostate-cancer mortality at 11 years of follow-up

21 January 2018

1 reference

Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer

21 January 2018

1 reference

Prostate needle biopsies: interobserver variation and clinical consequences of histopathological re-evaluation.

21 January 2018

1 reference

Is it possible to predict low-volume and insignificant prostate cancer by core needle biopsies?

21 January 2018

1 reference

Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy

21 January 2018

1 reference

Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare

21 January 2018

1 reference

The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance

21 January 2018

1 reference

Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy

21 January 2018

1 reference

Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program

21 January 2018

1 reference

Prostate-specific antigen levels as a predictor of lethal prostate cancer

21 January 2018

1 reference

Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.

21 January 2018

1 reference

Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).

21 January 2018

1 reference

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

21 January 2018

1 reference

Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program

21 January 2018

1 reference

Prostate cancer active surveillance and health-related quality of life: results of the Finnish arm of the prospective trial

21 January 2018

1 reference

Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer

21 January 2018

1 reference

The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer.

21 January 2018

1 reference

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

21 January 2018

1 reference

A panel of TMPRSS2:ERG fusion transcript markers for urine-based prostate cancer detection with high specificity and sensitivity

21 January 2018

1 reference

Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study

21 January 2018

1 reference

A miRNA expression signature that separates between normal and malignant prostate tissues.

21 January 2018

1 reference

ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer.

21 January 2018

1 reference

Radical prostatectomy versus watchful waiting in early prostate cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JSO.23584

1 reference

30 August 2017

1 reference